Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Psoriasis
Interventions: MEDI-507; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 3
States / cities: Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington

Conditions: Ovarian Neoplasms, Ascites
Interventions: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Submental Fat
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Athletic Performance, Neuromuscular Adaptations, Lower Limb, Chiropractic Manipulation
Interventions: Manual Therapy Procedure: Chiropractic Ankle Manipulation; Other
Lead sponsor: Northeast College of Health Sciences; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seneca Falls, New York

Conditions: Gastroesophageal Reflux
Interventions: Dexlansoprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Placebo, Tivantinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more

Conditions: Opioid Dependence, Methadone Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Geographic Atrophy of the Macula
Interventions: GAL-101, Placebo; Drug
Lead sponsor: Galimedix Therapeutics Inc; Industry
Eligibility: 55 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland

Conditions: Alzheimer's Disease
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), NICE Cognitive Training; Device · Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 55 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy, Benign Neonatal
Interventions: Phenobarbital Sodium Injection; Drug
Lead sponsor: NEMA Research, Inc.; Industry
Eligibility: 34 Weeks to 44 Weeks
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Melanoma
Interventions: Epacadostat, ipilimumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Literacy
Interventions: Intervention Group; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Acute Schizophrenia
Interventions: Brexpiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Anaheim, California • Cerritos, California • Garden Grove, California + 10 more

Conditions: Hereditary Angioedema
Interventions: Donidalorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more

Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Interventions: AG10, Placebo; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Conditions: Executive Function, Behavioral Research, Schools, Behavior Therapy
Interventions: Organizational Skills Training - Tier 2 (OST-T2); Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Insulin Lispro (U100); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more

Conditions: Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 13
States / cities: Jacksonville, Florida • Alpharetta, Georgia • Macon, Georgia + 9 more

Conditions: Acute Ischemic Stroke
Interventions: natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 13 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin plus metformin IR, Placebo plus metformin IR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Concord, California • Fountain Valley, California • Lomita, California + 22 more

Conditions: Body Weight
Interventions: Weight Management Formulation, Placebo, Handout with Suggestions for Healthy Eating and Overall Health; Dietary Supplement · Other
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Search by objective public record fields.

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Squat Jump Performance and Chiropractic Ankle Manipulation

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Assuring Patient-centered Literacy Promotion for Underserved Children Study

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Organizational Skills Training - Tier 2 (OST-T2)

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Study to Evaluate the Effects of a Weight Management Program on Body Weight

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome